Upregulates GLS activity during ischemia and declines during reperfusion. Applying a GLS antagonist mitigated both IRI- and cisplatin-induced kidney function deterioration by inhibiting the activation and proliferation of T cells (Lee et al., 2023). The gene discussed is GLS; the disease is ischemia.